Unity Health Toronto

Joshua Orson reflects on his journey from addiction to becoming a peer support worker at a new, 36-bed detox centre in Toronto, emphasizing the space's role in fostering dignity and hope. The centre, operated by Unity Health Toronto and funded by the Ministry of Health, offers free services including group and individual therapy. Despite being full, the centre frequently has openings due to its short-term residential design. The demand highlights a severe shortage of detox beds in Ontario, where opioid overdose deaths have surged. The province plans to shift from supervised consumption sites to new recovery hubs and supportive housing units.

Joshua Orson reflects on his journey from addiction to becoming a peer support worker at a new, 36-bed detox centre in Toronto, emphasizing the space's role in fostering dignity and hope. The centre, operated by Unity Health Toronto and funded by the Ministry of Health, offers free, 24-hour care and is one of four publicly funded residential detox facilities in the city. The centre's design aims to convey care and love, crucial for both patient recovery and staff well-being, amidst a severe shortage of detox beds and the ongoing opioid crisis.

GLORIOUS study finds no improvement in clinical outcomes from using GLP-1 receptor agonist or restrictive oxygenation during CPB-assisted coronary artery surgery and/or valve replacement surgery.

Arch Biopartners' phase II trial for LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI), has begun patient recruitment and dosing in Canada. The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery. LSALT peptide, Arch Biopartners' lead drug candidate, targets the dipeptidase-1 (DPEP1) pathway to prevent ischemia-reperfusion injury.

Arch Biopartners Inc. announces the start of patient recruitment and dosing in Canada for the Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The University of Calgary has already dosed the first patient, while Toronto General Hospital and St. Michael's Hospital are finalizing approvals. The trial aims to evaluate the percentage of subjects with AKI within seven days post-surgery, using a randomized, double-blind, placebo-controlled approach with a target of 240 patients.

Arch Biopartners Inc. announced the start of patient recruitment and dosing in Canada for its Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with AKI within seven days following on-pump cardiac surgery. The first patient has been dosed at the University of Calgary, with additional sites in Toronto awaiting final approvals.

Arch Biopartners Inc. announces the start of patient recruitment and dosing in Canada for the Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI). The University of Calgary has already dosed the first patient, and Toronto hospitals are finalizing approvals. The trial aims to evaluate the percentage of subjects with AKI within seven days post-surgery, using KDIGO criteria.